Core Concepts
Cefepime-taniborbactam is more effective than meropenem in treating complicated UTIs and acute pyelonephritis.
Abstract
The study compared the efficacy of Cefepime-taniborbactam and meropenem in treating complicated UTIs and acute pyelonephritis.
TOPLINE:
- Cefepime-taniborbactam showed 22% higher effectiveness than meropenem.
- Study published in The New England Journal of Medicine.
METHODOLOGY:
- Phase 3 trial with participants from 15 countries.
- Safety group of 657 patients and 436 in the micro intention-to-treat group.
- Efficacy measured by reduced bacteria levels and symptom resolution.
TAKEAWAY:
- Cefepime-taniborbactam group had higher efficacy than meropenem.
- 35.5% of patients in the Cefepime-taniborbactam group experienced mild to moderate adverse effects.
IN PRACTICE:
- Cefepime-taniborbactam was superior to meropenem for treating complicated UTIs.
- Safety profile similar to meropenem.
SOURCE:
- Study led by Paul McGovern, MD, from Venatorx Pharmaceuticals.
LIMITATIONS:
- No limitations reported by the authors.
DISCLOSURES:
- Study funded by Venatorx Pharmaceuticals with support from various organizations.
Stats
Cefepime-taniborbactam was 22% more effective than meropenem.
70.6% of patients in the cefepime-taniborbactam group showed a successful reduction in bacteria and symptoms compared with 58.0% in the meropenem group.
35.5% of patients in the cefepime-taniborbactam group experienced mild to moderate adverse effects.
Quotes
"Cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a safety profile similar to that of meropenem."